Henlius' HANSIZHUANG receives CHMP favorable opinion for first-line ES-SCLC treatment in Europe.

Henlius has received a favorable opinion from the CHMP for HANSIZHUANG, also known as HETRONIFLY, as a first-line treatment for extensive-stage small cell lung cancer in Europe. This approval, developed in partnership with Accord Healthcare and Intas, marks a significant step for patients facing this aggressive cancer.

September 21, 2024
3 Articles

Further Reading